Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

First patient dosed in Phase IIb imaging for Brain Mets

Monday, April 28, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has successfully dosed its first patient in a Phase IIb imaging study targeting brain metastases. This milestone indicates progress in their clinical development efforts. The company aims to enhance imaging techniques for better diagnosis and treatment of brain metastases.
Price reaction · baseline $4.07 (2025-04-25 close) · hit pre-market · 2 other RADX headline(s) in the window, move may be shared
day 0 close
-2%
day 1
-1.7%
day 3
-1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in Phase IIb imaging study.
  • Progress in clinical trials for Brain Mets.
  • Positive outlook for Radiopharm Theranostics.

Full Press Release Details

• Announcements
• Price Sensitive
• April 28, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• October 15, 2024
• Announcements
• December 22, 2023
• Announcements
• November 15, 2023
• Announcements
• October 23, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the significance of the first patient dosed?

Dosing the first patient marks a key milestone in the Phase IIb imaging study for brain metastases.

What is the focus of the Phase IIb study?

The study focuses on improving imaging techniques for diagnosing and treating brain metastases.

Who is conducting the Phase IIb imaging study?

The Phase IIb imaging study is being conducted by Radiopharm Theranostics.

What is the expected outcome of this study?

The study aims to enhance imaging capabilities for better management of brain metastases.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics brain metastases clinical trial imaging study
Last updated: Apr 28, 2025